Prosecution Insights
Last updated: October 04, 2026

Dunlap Codding, P.C. - Novocure GmbH

Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering

13 pending office actions • 2 clients • 12 examiners • 6 art units • 0 of 13 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days

Analysis

DUNLAP CODDING, P.C. - Novocure GmbH is a patent law firm focused on Medical Devices & Mechanical Engineering. The firm has a career total of 4693 applications, reflecting its extensive involvement in the patent process. It maintains a resolved allowance rate of 71.13 percent, demonstrating a consistent track record of success in securing patent protection. This performance is documented across its portfolio in Medical Devices & Mechanical Engineering. The firm's experience is a significant factor for its clients.

The firm currently has 12 pending office actions. Its average of 2.94 office actions per allowance provides a baseline for the expected level of interaction with the patent office. These metrics, including the 4693 career applications and the 71.13 percent allowance rate, offer a comprehensive view of the firm's expertise. The 2.94 average office actions per allowance is a critical data point for evaluating its prosecution efficiency for Novocure GmbH. These figures highlight the firm's operational consistency.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=4693 apps, methodology: how we score firms)

71.1%
Allowance Rate
n=4693
+0.44σ
Allowance Rate (norm)
n=4693
2.9
OAs to Allowance
n=2498
-0.28σ
OAs to Allow (norm)
n=2498
1011 days
Time to Allowance
n=2498
+20.3pp
Interview Lift
n=4693
17.0%
RCE Rate
n=4693
1.5%
Appeal Rate
n=4693

Rejection Performance (% of received rejections ultimately overcome)

75.3%
§101 Overcome
n=243
72.3%
§102 Overcome
n=931
74.1%
§103 Overcome
n=1520
76.4%
§112 Overcome
n=958

Specialization & Scale

B65D, A47G, Y10T
Top CPC Subclasses
18%
Top-3 CPC Share
n=4693
3
Practitioners
n=4693
1564.3
Apps / Practitioner
n=4693

Portfolio Summary

13
Total Pending OAs
11
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (54%)
5
Medium (38%)
1
Easy (8%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only4 (31%)
§112 only1 (8%)
Double-patenting + other1 (8%)
Multi-statute (no §101)7 (54%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
15% of docket
1
Information Tech
8% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
7
Mechanical / Eng
54% of docket
3
Business / Other
23% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

130 h
Manual time on pending OAs
26 h
Time saved (low, 20%)
46 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KAHELIN, MICHAEL WILLIAM 2 77.9% +23.9%
SISON, CHRISTINE ANDREA PAN 1 33.3% +37.7%
STUMPFOLL, DANA LYNN 1 53.3% +43.1%
HILSMIER, HEIDI ANN 1 58.3% +61.1%
SOLOMON, JOSHUA BRENDON 1 83.4% +20.3%
DINH, ANH-KHOA N 1 87.4% +15.2%
DEBERRY, REGINA M 1 50.1% +30.6%
BRETZ, COREY LANE 1 0.0% +0.0%
EVANISKO, GEORGE ROBERT 1 70.4% +34.9%
SAHAND, SANA 1 63.4% +23.8%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18398714 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND ANTI-VEGFR-2 ANTIBODIES DINH, ANH-KHOA N 34d

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18899709 TRANSDUCER ARRAY HAVING SUBARRAYS AND METHODS OF PRODUCTION AND USE THEREOF SISON, CHRISTINE ANDREA PAN —
18894349 LOW FREQUENCY RF ABLATION SYSTEM STUMPFOLL, DANA LYNN —
18743392 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND THIOREDOXIN/GLUTATHIONE INHIBITORS HILSMIER, HEIDI ANN —
18619957 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND KILLER CELLS SOLOMON, JOSHUA BRENDON —
18477010 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND DENDRITIC CELLS DEBERRY, REGINA M —
18336493 SYSTEMS AND METHODS FOR TREATING CONDITIONS AND DISEASES USING ALTERNATING ELECTRIC FIELDS AND CRISPR-CAS SYSTEM BRETZ, COREY LANE —
18333906 SYSTEMS AND METHODS FOR INCREASING INTESTINAL ABSORPTION OF THERAPEUTIC AGENTS EVANISKO, GEORGE ROBERT —

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18062372 GARMENT PROVIDING A BIASING FORCE ON A TRANSDUCER ARRAY SAHAND, SANA 8d overdue
18398714 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND ANTI-VEGFR-2 ANTIBODIES DINH, ANH-KHOA N 34d
18511374 CONDUCTIVE GEL COMPOSITIONS COMPRISING BULK ELECTRON TRANSPORT AGENTS AND METHODS OF PRODUCTION AND USE THEREOF KAHELIN, MICHAEL WILLIAM 75d
18899709 TRANSDUCER ARRAY HAVING SUBARRAYS AND METHODS OF PRODUCTION AND USE THEREOF SISON, CHRISTINE ANDREA PAN —
18894349 LOW FREQUENCY RF ABLATION SYSTEM STUMPFOLL, DANA LYNN —
18806445 CONNECTOR FOR DETACHABLE ARRAY KAHELIN, MICHAEL WILLIAM —
18743392 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND THIOREDOXIN/GLUTATHIONE INHIBITORS HILSMIER, HEIDI ANN —
18619957 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND KILLER CELLS SOLOMON, JOSHUA BRENDON —

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
Novocure 12
Novocure GmbH G 1

Top Art Units

Art UnitApps
37924
37962
37941
16471
16351
21891

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18899709 TRANSDUCER ARRAY HAVING SUBARRAYS AND METHODS OF PRODUCTION AND USE THEREOF Novocure GmbH SISON, CHRISTINE ANDREA PAN §103§112 Non-Final OA — Pending Sep 27, 2024
18894349 LOW FREQUENCY RF ABLATION SYSTEM Novocure GmbH STUMPFOLL, DANA LYNN 3794 §102§103 Non-Final OA — Pending Sep 24, 2024
18806445 CONNECTOR FOR DETACHABLE ARRAY Novocure GmbH KAHELIN, MICHAEL WILLIAM 3792 §102§103DP Non-Final OA — Pending Aug 15, 2024
18743392 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND THIOREDOXIN/GLUTATHIONE INHIBITORS Novocure GmbH G HILSMIER, HEIDI ANN §103§112 Non-Final OA — Pending Jun 14, 2024
18619957 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND KILLER CELLS Novocure GmbH SOLOMON, JOSHUA BRENDON §102§103 Non-Final OA — Pending Mar 28, 2024
18398714 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND ANTI-VEGFR-2 ANTIBODIES Novocure GmbH DINH, ANH-KHOA N 3796 §103 Non-Final OA 34d Pending Dec 28, 2023
18511374 CONDUCTIVE GEL COMPOSITIONS COMPRISING BULK ELECTRON TRANSPORT AGENTS AND METHODS OF PRODUCTION AND USE THEREOF Novocure GmbH KAHELIN, MICHAEL WILLIAM 3792 §112 Final Rejection 75d Pending Nov 16, 2023
18477010 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND DENDRITIC CELLS Novocure GmbH DEBERRY, REGINA M 1647 §102§103§112 Non-Final OA — Pending Sep 28, 2023
18336493 SYSTEMS AND METHODS FOR TREATING CONDITIONS AND DISEASES USING ALTERNATING ELECTRIC FIELDS AND CRISPR-CAS SYSTEM Novocure GmbH BRETZ, COREY LANE 1635 §102§103Other Non-Final OA — Pending Jun 16, 2023
18333906 SYSTEMS AND METHODS FOR INCREASING INTESTINAL ABSORPTION OF THERAPEUTIC AGENTS Novocure GmbH EVANISKO, GEORGE ROBERT 3792 §102§103§112Other Non-Final OA — Pending Jun 13, 2023
18062372 GARMENT PROVIDING A BIASING FORCE ON A TRANSDUCER ARRAY Novocure GmbH SAHAND, SANA 3796 §103 Non-Final OA 8d overdue Pending Dec 06, 2022
18062161 COMPACT DC SYSTEM FOR DELIVERING A SQUARE WAVE AC SIGNAL Novocure GmbH TEHRANI, DANIEL 3792 §103 Non-Final OA — Pending Dec 06, 2022
17698777 CONSTRUCTING A 3D PHANTOM WITH LIQUID HYDROGEL Novocure GmbH CALLE, ANGEL JAVIER 2189 §103 Final Rejection 3d overdue Pending Mar 18, 2022

Managing Dunlap Codding, P.C. - Novocure GmbH's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month